Explore

Research Links Poor Sleep to Increased Cancer Risk in Under-50s

Research Links Poor Sleep to Increased Cancer Risk in Under-50s

Recent studies presented at the American Society of Clinical Oncology's annual meeting in Chicago have highlighted a potential link between poor sleep patterns and an increased risk of early-onset cancers in individuals under 50. Conducted by the MD Anderson Cancer Center in Houston, the research analyzed health data from over 18 million U.S. adults aged 18 to 50. Findings suggest that those with irregular sleeping patterns are more likely to develop cancers such as bowel, breast, uterine, or ovarian cancer. In some cases, individuals diagnosed with insomnia were found to be three times more likely to develop cancer within five years. The studies underscore sleep disruption as a potentially modifiable risk factor in early-onset cancer risk stratification, warranting further investigation.

Studies Highlight Impact of Healthy Lifestyles on Childhood Cancer Survivors' Long-term Health

Studies Highlight Impact of Healthy Lifestyles on Childhood Cancer Survivors' Long-term Health

Recent international studies have revealed that adopting a healthy lifestyle can significantly reduce the risk of cardiovascular disease and other chronic health issues in childhood cancer survivors. Conducted by researchers at the University of Gothenburg and St. Jude Children's Research Hospital, these studies followed over 18,000 childhood cancer survivors for up to 30 years. The findings, published in Nature Communications and JACC: CardioOncology, indicate that lifestyle factors such as physical inactivity, obesity, smoking, and high alcohol intake contribute to chronic health problems in survivors. These factors are shown to have a comparable impact on long-term health as the cancer treatments themselves, such as radiation and chemotherapy. The research underscores the importance of lifestyle changes, which unlike past treatments, can be modified to improve health outcomes.

Jill Biden Reflects on Joe Biden's Prostate Cancer Diagnosis and Missed Detection

Jill Biden Reflects on Joe Biden's Prostate Cancer Diagnosis and Missed Detection

Former First Lady Jill Biden expressed her shock regarding President Joe Biden's prostate cancer diagnosis, which was revealed last year. In an interview, she mentioned that despite receiving excellent care at the White House, the condition was not detected earlier. The diagnosis came as a surprise to the Bidens, raising questions about the thoroughness of medical evaluations conducted during their time in the White House. Jill Biden's comments highlight the unexpected nature of the diagnosis and the challenges faced by the family in dealing with the health scare.

GRAIL's Galleri Test Enhances Early Cancer Detection at ASCO Meeting

GRAIL's Galleri Test Enhances Early Cancer Detection at ASCO Meeting

GRAIL, Inc. has presented the results of its PATHFINDER 2 study at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study involved 35,878 participants and evaluated the Galleri multi-cancer early detection (MCED) test. The test screens for over 50 types of cancer, including those without current screening options, such as pancreatic and ovarian cancers. The Galleri test demonstrated a 6.5-fold increase in cancer detection when added to standard screenings for breast, colorectal, cervical, and lung cancers. Notably, 71% of the new cancers detected were in stages I-III, allowing for potentially curative treatments. The test also showed a low false positive rate and high accuracy in predicting the cancer signal origin, facilitating efficient diagnostic evaluations.

President Trump Signs Executive Order to Reduce Recommended Childhood Vaccines

President Trump Signs Executive Order to Reduce Recommended Childhood Vaccines

President Trump has signed an executive order directing the Centers for Disease Control and Prevention (CDC) to reduce the number of vaccines recommended for children. This order follows a scientific assessment by the Department of Health and Human Services (HHS) that compared U.S. childhood immunization recommendations with those of peer nations. The assessment, co-authored by vaccine skeptic Dr. Tracy Beth Høeg, suggests maintaining vaccines for ten diseases, including measles and polio, while removing others such as hepatitis A and B, meningitis, and influenza from the recommended schedule. The order mandates the CDC and its Advisory Committee on Immunization Practices (ACIP) to review this assessment and update the vaccine schedule accordingly.

Labcorp Collaborates on National Trial to Enhance Genetic Testing in Colorectal Cancer

Labcorp Collaborates on National Trial to Enhance Genetic Testing in Colorectal Cancer

Labcorp has announced a collaboration with the Alliance for Clinical Trials in Oncology to conduct a national, multicenter clinical trial aimed at improving genetic testing for colorectal cancer (CRC). The trial will focus on increasing germline genetic testing among at-risk family members and evaluating the impact of multigene panel testing on newly diagnosed patients. Labcorp will serve as the exclusive genetic testing provider, leveraging its Invitae testing capabilities. The trial is sponsored by the National Cancer Institute and involves participation from the NCI National Clinical Trials Network, including sites in Puerto Rico. The study aims to improve the participation of first-degree relatives in genetic testing through proactive outreach by healthcare providers.

Blood Testing Added to Colorectal Cancer Screening Recommendations by American Cancer Society

Blood Testing Added to Colorectal Cancer Screening Recommendations by American Cancer Society

The American Cancer Society has updated its colorectal cancer screening guidelines to include blood testing as an option for adults aged 45 and older. This addition aims to provide an alternative for individuals who decline or cannot complete traditional screening methods like colonoscopies or stool-based tests. The blood test, known as the Shield test, was approved by the FDA in 2024 and offers a less invasive option for detecting colorectal cancer.

Melanoma Focus Launches Campaign to Train Barbers in Skin Cancer Detection

Melanoma Focus Launches Campaign to Train Barbers in Skin Cancer Detection

Melanoma Focus Launches Campaign to Train Barbers in Skin Cancer Detection

FDA advisers to weigh composition of COVID vaccines for 2026-2027

FDA advisers to weigh composition of COVID vaccines for 2026-2027

By Christy Santhosh May 28 (Reuters) - The U.S.

Gen Z's Tanning Habits Raise Skin Cancer Concerns

Gen Z's Tanning Habits Raise Skin Cancer Concerns

Gen Z's Tanning Habits Raise Skin Cancer Concerns

Study Finds Non-Intoxicating Cannabinoids May Alleviate Chronic Pain

Study Finds Non-Intoxicating Cannabinoids May Alleviate Chronic Pain

Study Finds Non-Intoxicating Cannabinoids May Alleviate Chronic Pain

Study Identifies Key Predictors of Biosafety Incidents Leading to Outbreaks

Study Identifies Key Predictors of Biosafety Incidents Leading to Outbreaks

A comprehensive analysis of over a century of laboratory biosafety incidents has identified key factors that predict the likelihood of disease outbreaks and fatalities. Conducted by researchers at Mahidol University in Bangkok, the study examined 1,126 incidents from 1900 to 2025, finding that operational failures, lab settings, and personnel types significantly influence outbreak risks. The study highlights that failures to inactivate pathogens, leaks involving infectious aerosols, and poor waste handling are major contributors to outbreaks. Additionally, handling animals in labs increases outbreak risks, while antibody testing poses lower risks. The type of lab and personnel involved also affect the likelihood of outbreaks, with clinical and academic labs more prone to incidents than research labs.